Poseida Therapeutics announced the appointment of Syed Rizvi, M.D., as Chief Medical Officer effective April 1. Dr. Rizvi is a seasoned executive with over 20 years of experience across all stages of drug development, including clinical strategy, execution, and commercialization. Dr. Rizvi most recently served as Chief Medical Officer of Caribou Biosciences, where he was responsible for overall strategy and execution of all clinical development programs.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PSTX:
- Poseida Therapeutics granted FDA orphan designation for P-BCMA-ALLO1
- Poseida Therapeutics’ treatment of multiple myeloma gets FDA orphan designation
- 3 Best Stocks to Buy Now, 3/11/2024, According to Top Analysts
- Poseida Therapeutics Announces Executive Leadership Change
- Poseida Therapeutics reports Q4 EPS (27c), consensus (39c)
